EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms EXTEND
- 20 Dec 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Feb 2018.
- 15 Dec 2017 Planned End Date changed from 31 Dec 2018 to 1 Jul 2018.
- 15 Dec 2017 Planned primary completion date changed from 31 Dec 2018 to 1 Jul 2018.